The Role of BCR-ABL P190 in Diagnosis and Prognosis of ALL patients
Archives of Medical Laboratory Sciences,
Vol. 1 No. 3 (2015),
20 December 2015
https://doi.org/10.22037/amls.v1i3.11827
Abstract
Acute lymphoblastic leukemia(ALL) is due to early stage arrest of lymphoblast development. The translocation of Philadelphia (Ph) chromosome occurs as a result of the BCR-ABL fusion gene, which constitutively produced activated tyrosine kinase. This gene fusion is an important indicator for prognosis in ALL and is associated with poor overall survival and remission duration. BCR-ABL could interfere in establishment of ALL. Therefore, in this study, we will try to investigate most pathological aspects involved in BCR-ABL fusion. Strategies for genetic alterations in B-ALL pathogenesis are discussed. Then, the main cytogenetic changes and genetic subtypes for ALL are highlighted. Moreover, intermediate reactions between cancer stem cells (CSC) related to ALL, its niche and microenvironment is discussed. The main objective in this review is to understand the principle prognosis in ALL to introduce new approaches and treatment alternatives.
- Acute lymphoblastic leukemia
- Philadelphia chromosome
- tyrosine kinase.
How to Cite
References
Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. 1973.
Heisterkamp N, Groffen J, Stephenson JR, Spurr N, Goodfellow P, Solomon E, et al. Chromosomal localization of human cellular homologues of two viral oncogenes. 1982.
Konopka JB, Watanabe SM, Singer JW, Collins SJ, Witte ON. Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration. Proceedings of the National Academy of Sciences. 1985;82(6):1810-4.
Morel F, Herry A, Le Bris M-J, Morice P, Bouquard P, Abgrall J-F, et al. Contribution of fluorescence in situ hybridization analyses to the characterization of masked and complex Philadelphia chromosome translocations in chronic myelocytic leukemia. Cancer genetics and cytogenetics. 2003;147(2):115-20.
Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiedemann LM. The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Research. 1995;55(1):34-8.
Soler G, Radford-Weiss I, Ben-Abdelali R, Mahlaoui N, Ponceau J, Macintyre E, et al. Fusion of ZMIZ1 to ABL1 in a B-cell acute lymphoblastic leukaemia with at (9; 10)(q34; q22. 3) translocation. Leukemia. 2008;22(6):1278-80.
Lee J, Beliakoff J, Sun Z. The novel PIAS-like protein hZimp10 is a transcriptional co-activator of the p53 tumor suppressor. Nucleic acids research. 2007;35(13):4523-34.
De Keersmaecker K, Graux C, Odero MD, Mentens N, Somers R, Maertens J, et al. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t (9; 14)(q34; q32). Blood. 2005;105(12):4849-52.
Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R, et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nature genetics. 2004;36(10):1084-9.
De Braekeleer E, Douet-Guilbert N, Le Bris M, Berthou C, Morel F, De Braekeleer M. A new partner gene fused to ABL1 in at (1; 9) (q24; q34)-associated B-cell acute lymphoblastic leukemia. Leukemia. 2007;21(10):2220-1.
Mustjoki S, Hernesniemi S, Rauhala A, Kähkönen M, Almqvist A, Lundán T, et al. A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t (1; 9)(q24; q34). haematologica. 2009;94(10):1469-71.
Eyers Cxae, McNeill H, Knebel A, Morrice N, Arthur Sxajxac, Cuenda A, et al. The phosphorylation of CapZ-interacting protein (CapZIP) by stress-activated protein kinases triggers its dissociation from CapZ. Biochem J. 2005;389:127-35.
Hidalgo‐Curtis C, Chase A, Drachenberg M, Roberts MW, Finkelstein JZ, Mould S, et al. The t (1; 9)(p34; q34) and t (8; 12)(p11; q15) fuse pre‐mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1. Genes, Chromosomes and Cancer. 2008;47(5):379-85.
Shav-Tal Y, Zipori D. PSF and p54 nrb/NonO–multi-functional nuclear proteins. FEBS letters. 2002;531(2):109-14.
Wang JY. Abl tyrosine kinase in signal transduction and cell-cycle regulation. Current opinion in genetics & development. 1993;3(1):35-43.
Colicelli J. ABL tyrosine kinases: evolution of function, regulation, and specificity. Science signaling. 2010;3(139):re6.
GREGOIRE M, GERMAIN D, CHARRIN C, PAGES M, PHILLIPE N, SOUILLET G, et al. Collaborative study of karyotypes in childhood acute lymphoblastic leukemias. Leukemia. 1993;7(1):10-9.
Secker-Walker L, Craig J, Hawkins J, Hoffbrand A. Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia. 1991;5(3):196-9.
Charrin C, Magaud J, Sebban C, Fiere D, Dastugue N, HuguetRigal F, et al. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings and outcome. A collaborative study of the Groupe Français de Cytogénétique Hématologique. Blood. 1996;87(8):3135-42.
De Braekeleer E, Basinko A, Douet-Guilbert N, Morel F, Le Bris M-J, Berthou C, et al. Cytogenetics in pre-B and B-cell acute lymphoblastic leukemia: a study of 208 patients diagnosed between 1981 and 2008. Cancer genetics and cytogenetics. 2010;200(1):8-15.
Westbrook CA, Hooberman AL, Spino C, Dodge RK, Larson RA, Davey F, et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood. 1992;80(12):2983-90.
Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nature Reviews Immunology. 2008;8(5):380-90.
Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. BLOOD-NEW YORK-. 1996;88:2375-84.
Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood. 2009;114(13):2688-98.
Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin MG, Liu W, Zhang J, et al. Rearrangement of CRLF2 in B-progenitor–and Down syndrome–associated acute lymphoblastic leukemia. Nature genetics. 2009;41(11):1243-6.
Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H, Reid AG, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008;112(12):4437-44.
de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. Journal of Clinical Oncology. 2008;26(20):3358-63.
Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood. 1998;91(11):3995-4019.
Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 2010;115(2):206-14.
Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome–positive leukemias: from basic mechanisms to molecular therapeutics. Annals of internal medicine. 2003;138(10):819-30.
Larson RA, editor Management of acute lymphoblastic leukemia in older patients. Seminars in hematology; 2006: Elsevier.
Faderl S, Kantarjian HM, Thomas DA, Cortes J, Giles F, Pierce S, et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leukemia & lymphoma. 2000;36(3-4):263-73.
Gleißner B, Gökbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood. 2002;99(5):1536-43.
Wetzler M, Dodge RK, Mrózek K, Stewart CC, Carroll AJ, Tantravahi R, et al. Additional cytogenetic abnormalities in adults with Philadelphia chromosome‐positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. British journal of haematology. 2004;124(3):275-88.
Voncken J, Kaartinen V, Pattengale P, Germeraad W, Groffen J, Heisterkamp N. BRC/ABL P210 and P190 Cause Distinct Leukemia in Transgenic Mice. Blood. 1.۱۱-٤٦۰۳:(۱۲)۸٦;۹۹٥
Rieder H, Ludwig WD, Gassmann W, Maurer J, Janssen JW, Gökbuget N, et al. Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia. British journal of haematology. 1996;95(4):678-91.
Heerema N, Harbott J, Galimberti S, Camitta B, Gaynon P, Janka-Schaub G, et al. Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia. 2004;18(4):693-702.
Seegmiller AC, Kroft SH, Karandikar NJ, McKenna RW. Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia. American journal of clinical pathology .2009;6(132):290-4.
Hrusak O, Porwit-MacDonald A. Antigen expression patterns reflecting genotype of acute leukemias. Leukemia. 2002;16(7):1233-58.
Primo D, Tabernero M, Perez J, Rasillo A, Sayagues J, Espinosa A, et al. Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics. Leukemia. 2005;19(5):713-20.
Tabernero M, Bortoluci A, Alaejos I, Lopez-Berges M, Rasillo A, Garcia-Sanz R, et al. Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expression. Leukemia. 2001;15(3):406-14.
Udomsakdi-Auewarakul C, Promsuwicha O, Tocharoentanaphol C ,Munhketvit C, Pattanapanyasat K, Issaragrisil S. Immunophenotypes and outcome of Philadelphia chromosome-positive and-negative Thai adult acute lymphoblastic leukemia. International journal of hematology. 2003;78(4):337-43.
Paietta E, Racevskis J, Neuberg D, Rowe J, Goldstone A,Wiernik P. Expression of CD25 (interleukin-2 receptor alpha chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: results of a preliminary laboratory analysis of ECOG/MRC Intergroup Study E2993. Eastern Cooperative Oncology Group/Medical Research Council. Leukemia. 1997;11(11):1887-90.
Attarbaschi A, Mann G, König M, Steiner M, Strehl S, Schreiberhuber A, et al. Mixed Lineage Leukemia–rearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity. Clinical cancer research. 2006;12(10):2988-94.
Abdelhaleem M. Frequent but nonrandom expression of myeloid markers on de novo childhood acute lymphoblastic leukemia. Experimental and molecular pathology. 2007;83(1):138-41.
Bene M, Castoldi G, Knapp W, Ludwig W, Matutes E, Orfao A, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias)EGIL). Leukemia. 1995;9(10):1783-6.
Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, et al. BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453(7191):110-4.
Martinelli G, Iacobucci I, Storlazzi CT, Vignetti M, Paoloni F, Cilloni D, et al. IKZF1 (Ikaros) deletions in BCR-ABL1–positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. Journal of Clinical Oncology. 2009;27(31):5202-7.
Harvey RC, Mullighan CG, Chen I-M, Wharton W, Mikhail FM, Carroll AJ, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 2010;115(26):5312-21.
Cario G, Zimmermann M, Romey R, Gesk S, Vater I, Harbott J, et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non–high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood. 2010;115(26):5393-7.
Ensor HM, Schwab C, Russell LJ, Richards SM, Morrison H, Masic D, et al. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood. 2011;117(7):2129-36.
Chen I-M, Harvey RC, Mullighan CG, Gastier-Foster J, Wharton W, Kang H, et al. Outcome modeling with CRLF2, IKZF1 ,JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 2012;119(15):3512-22.
Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer cell. 2012;22(2):153-66.
Zenatti PP, Ribeiro D, Li W, Zuurbier L, Silva MC, Paganin M, et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nature genetics. 2011;43(10):932-9.
Harrison CJ. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. British journal of haematology. 2009;144(2):147-56.
Pui C-H, Robison LL, Look AT. Acute lymphoblastic leukaemia. The Lancet. 2008;371(9617):1030-43.
Shurtleff S, Buijs A, Behm F, Rubnitz J, Raimondi S, Hancock M, et al. TEL/AML1 fusion resulting from a cryptic t (12; 21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia. 1995;9(12):1985-9.
Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481(7380):157-63.
Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36(1):93-9.
McWHIRTER JR, Galasso DL, Wang J. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Molecular and cellular biology. 1993;13(12):7587-95.
Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96(10):3343-56.
Deininger MW, Vieira S, Mendiola R, Schultheis B, Goldman
JM, Melo JV. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer research. 2000;60(7):2049-55.
Goldman JM, Melo JV. Chronic myeloid leukemia—advances in biology and new approaches to treatment. New England Journal of Medicine. 2003;349(15):1451-64.
Chissoe SL, Bodenteich A, Wang Y-F, Wang Y-P, Burian D,Clifton SW, et al. Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. Genomics. 1995;27(1):67-82.
Pawson T. Protein modules and signalling networks. 1995.
Van Etten RA, Jackson P, Baltimore D. The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell. 1989;58(4):669-78.
Miao Y-J, Wang JY. Binding of A/T-rich DNA by three high mobility group-like domains in c-Abl tyrosine kinase. Journal of Biological Chemistry. 1996;271(37):22823-30.
McWhirter JR, Wang J. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. The EMBO Journal. 1993;12(4):1533.
Epstein FH, Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, et al. The biology of chronic myeloid leukemia. New England Journal of Medicine. 1999;341(3):164-72.
Pane F, Intrieri M, Quintarelli C, Izzo B, Muccioli GC, Salvatore F. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. Oncogene. 2002;21(56):8652-67.
Groffen J, Heisterkamp N. The BCR/ABL hybrid gene.Bailliere's clinical haematology. 1987;1(4):983-99.
Clark SS, McLaughlin J, Timmons M, Pendergast AM, Ben-Neriah Y, Dow LW, et al. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science. 1988;239(4841):775-7.
Faderl S, Garcia‐Manero G, Thomas DA, Kantarjian HM. Philadelphia chromosome‐positive acute lymphoblastic leukemia–current concepts and future perspectives. Reviews in clinical and experimental hematology. 2002;6(2):142-60.
Saglio G, Guerrasio A, Rosso C, Zaccaria A, Tassinari A, Serra A, et al. New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 1990;76(9):1819-24.
Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R,et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood. 1996;88(7):2410-4.
Hochhaus A, Reiter A, Skladny H, Melo J, Sick C, Berger U, etal. A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. Blood. 199 .40-2236:(٦)۸۸;٦
How G, Lim L, Kulkarni S, Tan L, Tan P, Cross N. Two patients with novel BCR/ABL fusion transcripts (e8/a2 and e13/a2) resulting from translocation breakpoints within BCR exons. British journal of haematology. 1999;105(2):434-6.
Park IJ, Lim YA, Lee WG, Park JS, Kim HC, Lee H-J, et al. A case of chronic myelogenous leukemia with e8a2 fusion transcript. Cancer genetics and cytogenetics. 2008;185(2):106-8.
Colla S, Sammarelli G, Voltolini S, Crugnola M, Sebastio P,Giuliani N. e٦a2 BCR-ABL transcript in chronic myeloid leukemia:
is it associated with aggressive disease? Haematologica. 2004;89(5):611-3.
Hayette S, Tigaud I, Thomas X, French M, Perrin M, Nicolini F, et al. Identification of a rare e6a2 BCR-ABL fusion gene during the disease progression of chronic myelomonocytic leukemia: a case report. Leukemia. 2004;18(10):1735-6.
Quentmeier H, Cools J, MacLeod R, Marynen P, Uphoff C,Drexler H. e6-a2 BCR-ABL1 fusion in T-cell acute lymphoblastic leukemia. Leukemia. 2005 .٦-۲۹٥:(۲)۱۹;
Grégoire M-J, Latger-Cannard V, Staal A, Bologna S, Leotard B, Rault J-P, et al. Identification of an acute basophilic leukaemia carrying a rare e6a2 BCR-ABL transcript. Acta haematologica. 2006;116(3):216-8.
Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. New England Journal of Medicine. 2009;360(5):470-80.
Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR,Schulman BA, Phillips LA, et al .JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences. 2009;106(23):9414-8.
Dombret H, Gabert J, Boiron J-M, Rigal-Huguet F, Blaise D,Thomas X, et al. Outcome of treatment in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia—results of the prospective multicenter LALA-94 trial. Blood. 2002;100(7):2357-66.
Thomas X, Thiebaut A, Olteanu N, Danaila C, Charrin C,Archimbaud E, et al. Philadelphia chromosome positive adult acute lymphoblastic leukemia: characteristics, prognostic factors and treatment outcome. Hematology and cell therapy. 1998;40(3):119-28.
Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clinical Cancer Research. 2006;12(24):7374-9.
Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, etal. High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002;9 .5-3472:(9)9.
Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J,Binckebanck A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2007;110(2):727-34.
Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109(8):3189-97.
Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL–positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. Journal of clinical oncology. 2006;24(3):460-6.
Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J,Stelljes M, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2006;108(5):1469-
.77
O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer research. 2005;65(11):4500-5.
Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL.Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399-401.
Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome–positive leukemias. New England Journal of Medicine. 2006;354(24):2531-41.
Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, etal. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia. Blood. 2010;116(12):2070-7.
Foà R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. Blood. 2011;118(25):6521-8.
Gruber F, Mustjoki S, Porkka K. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome‐positive acute lymphoblastic leukaemia .British journal of haematology. 2009;145(5):581-97.
Kebriaei P, Saliba R, Rondon G, Chiattone A, Luthra R,Anderlini P, et al. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biology of Blood and Marrow Transplantation. 2012;18(4):584-92.
Yanada M, Sugiura I, Takeuchi J, Akiyama H, Maruta A,Ueda Y, et al. Prospective monitoring of BCR‐ABL1 transcript levels in patients with Philadelphia chromosome‐positive acute lymphoblastic leukaemia undergoing imatinib‐combined chemotherapy. British journal of haematology. 2008;143(4):503-10.
Ribera J-M, Oriol A, González M, Vidriales B ,Brunet S,Esteve J, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. haematologica. 201 .95-87:(1)95;۰
Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ,
Ehninger G, et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph‐positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study .American journal of hematology. 2010;85(3):164-70.
Champagne MA, Capdeville R, Krailo M, Qu W, Peng B,Rosamilia M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood. 2004;104(9):2655-60.
Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106(12):3760-7.
Mortuza FY, Papaioannou M, Moreira IM, Coyle LA,Gameiro P, Gandini D, et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. Journal of Clinical Oncology. 2002;20(4):1094-104.
Preudhomme C, Henic N, Cazin B, Lai J, Bertheas M, Vanrumbeke M, et al. Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL). Leukemia. 1997;11(2):294-8.
Pane F, Cimino G, Izzo B, Camera A, Vitale A, Quintarelli C, etal. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia. 2005;19(4):628-35.
Ottmann OG, Wassmann B, Pfeifer H, Giagounidis A, Stelljes M, Dührsen U, et al. Imatinib compared with chemotherapy as front‐line treatment of elderly patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ ALL). Cancer. 2007;109(10):2068-76.
Lee S, Kim DW, Cho B, Kim YJ, Kim YL, Hwang JY, et al.Risk factors for adults with Philadelphia‐chromosome‐positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real‐time quantitative reverse‐transcription polymerase chain reaction. British journal of haematology. 2003;120(1):145-53.
Delannoy A, Delabesse E, Lheritier V ,Castaigne S, Rigal-
Huguet F, Raffoux E, et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia. 2006 -1526:(9)20;
.32
Pfeifer H, Lange T, Wystub S, Wassmann B, Maier J, Binckebanck A, et al. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. Leukemia. 2012;26(7):1475-81.
Wassmann B, Pfeifer H, Stadler M, Bornhauser M, Bug G,
Scheuring UJ, et al. Early molecular response to posttransplantation imatinib determines outcome in MRD^+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). BLOOD-NEW YORK-. 2005;106(2):458.
- Abstract Viewed: 485 times
- PDF Downloaded: 411 times